Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

RAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma

Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.

Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept

Merck to Present at the Barclays 2023 Global Healthcare Conference

Two of Merck's new drugs could generate north of $10 billion in peak sales, an analyst said Tuesday. The post Keytruda Who?

Keytruda Who? Merck Nears Breakout On $10 Billion Sales Potential For Heart Drugs

Merck & Co., Inc. (NYSE:MRK ) Special Call (Investor Event at ACC.23/WCC) March 6, 2023 7:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dean Li - President, Merck Research Laboratories Joerg Koglin - VP, Global Clinical Development, CV & Respiratory Eliav Barr - SVP, Head, Global Clinical Development & CMO Jannie Oosthuizen - President, Human Health US Chirfi Guindo - CMO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Schott - JPMorgan Carter Gould - Barclays Tim Anderson - Wolfe Research Colin Bristow - UBS Malcolm Hoffman - BMO Capital Markets Nishant Gandhi - Truist Securities Operator Thank you for standing by Welcome to the Merck & Co. Investor Event at ACC.23/WCC. At this time, all participants are in a listen-only mode until the question-and-answer session of today's conference.

Merck & Co., Inc. (MRK) Presents at Special Call (Investor Event at ACC.23/WCC) (Transcript)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.

Merck's Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy

Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S.

US FDA Approves Intramuscular Administration for Merck's MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

Apple

Celsius Holdings

Salesforce

Chevron

New Oriental Education & Technology Group

Enphase Energy

JPMorgan Chase & Co

Coca-Cola

Northern Oil and Gas

Procter & Gamble

Superior Industries International

Walmart

Two new Breakout Stocks for Week 10 with better than 10% short-term upside and a Dow 30 Picks. Average cumulative returns for 2023 are +38.0% YTD. The Momentum Gauges® were negative from Week 8 with a positive signal late in Week 9. ARAV jumped 12% to end the week with strong momentum.

MDA Breakout Stocks Week 10 - March 2023: High-Frequency Gainers To Give You An Edge

Cisco Systems

Mastercard

Microsoft

Visa

The fourth quarter of 2022 marked a slight recovery for equity markets as they recouped some of their losses from the rest of the year. The S&P 500 climbed 7.6% for the quarter to end the year with a loss of 18.1%, while the Nasdaq narrowed its loss to 0.8% for the quarter to end the year down 32.5% and the Dow Jones Industrial Average popped 15.3% for a full-year drawdown of just 8.7%.

The Most-Sold Guru Stocks of the 4th Quarter

Freeport-McMoRan

Johnson & Johnson

Mondelez

Exxon Mobil

Eli Salzmann, manager of the Neuberger Berman Large Cap Value Fund (NPRTX), doesn't expect the early-year stock market rally to last. The post This Top Fund Manager Expects A Big Drop In Stocks appeared first on Investor's Business Daily.

This Top Fund Manager Expects A Big Drop In Stocks

Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer

In pivotal study, KEYTRUDA® (pembrolizumab) in combination with chemotherapy before surgery and continuing as a single agent after surgery showed a statistically significant improvement in EFS versus pre-operative chemotherapy

Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer

Merck is an American biopharma powerhouse that has generated consistent compounding growth, increasing its top line and EPS. Merck expects to deploy capital through strategic small bolt-on acquisitions, which we are a big fan of, rather than rampant big indiscriminate acquisitions.

Merck: All Eyes On Key Clinical Catalyst In March

iShares Select Dividend ETF

Home Depot

PepsiCo

In saying that, some dividend ETFs stand head and shoulders above others, measured by their total return. In this case, the best dividend ETF is the Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD), which has delivered a 233.34% total return over the last ten years, also beating the total returns of the S&P 500 over the same period.

What is the Best Dividend ETF?

Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789

Although investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential, we believe this gap will narrow in favor of Merck.

Merck Stock Looks Better Priced Compared To Its Sector Peer

Aravive Inc

Disney

Permian Basin Royalty Trust

Two new Breakout Stocks for Week 9 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are +35.8% YTD. This week, the Momentum Gauges® turned negative for the first time in 2023 with an early negative test signal Feb. 3rd warning of deteriorating market conditions.

MDA Breakout Stocks Week 9 - March 2023: High-Frequency Gainers To Give You An Edge

AbbVie

Biogen

Do you have these three biotech stocks on your watchlist right now?

3 Biotech Stocks To Watch Ahead Of March 2023

Merck & Co., Inc. stock has performed very well for me during the past two years. It often takes several years for the prices of overvalued or undervalued stocks to reflect today's earnings-based valuations.

Where Will Merck Stock Be In 4 Years?

Merck & Co. Inc. MRK, +1.31% and privately held Ridgeback Biotherapeutics said Friday a panel advising the European regulator has recommended refusing the marketing authorization for their jointly developed COVID antiviral for the treatment of certain adults. The companies said they would appeal the decision and request a review of the opinion, which was offered by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

Merck and Ridgeback Biotherapeutics to appeal advisory panel to EU regulator's decision to recommend refusing authorization of their COVID antiviral

Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)

The current drop in 2023 sales likely won't matter in the long term.

Don't Get Panicked Into Selling Off Merck Shares

In 2022, Merck's KEYTRUDA and GARDASIL worldwide sales increased by 27% YoY. The immunotherapy and HPV vaccines markets are expected to grow in the following years.

Merck: KEYTRUDA And GARDASIL Sales Are Expected To Rise

Moderna

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The FDA granted Breakthrough Therapy Designation based on positive data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial.

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela

News for Merck Stock (MRK)